Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Below is the Intel block diagram for the Z690 with 12th gen. CPUs [source]. Consider the PCIe lanes coming off the top left of the chipset in the diagram. The ones I've noted with the green arrows. Do ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

According to @godofprompt, recursive prompting is an AI technique where system outputs are fed back in as inputs to refine solutions through multiple iterations (source: @godofprompt, Dec 16, 2025).

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is slated to report third-quarter 2025 results on Nov. 5, before the opening bell.

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Visualize recursion in real-time — watch the call stack grow & shrink with stack and tree views. Built with HTML, CSS, JS (Canvas).